Novavax begins phase I trial of VLP-based vaccine candidate for A(H7N9) influenza
Clinical-stage biopharmaceutical company Novavax has initiated phase I of a clinical trial by enrolling participants to evaluate its monovalent virus-like particle (VLP) vaccine candidate to prevent A/Anhui/1/13-like A(H7N9) avian influenza viruses (…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Clinical Trials | Influenza | Influenza Vaccine | Pharmaceuticals | Vaccines